Refractory Multiple Myeloma Treatment Market Segmented By Immunomodulatory drugs (IMiDs), Cytotoxic agents, High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT), Allogeneic Stem Cell Transplantation Treatment with Distribution Channel in Hospitals, Cancer Institutes, Ambulatory Surgical Centers
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP29806
Multiple myeloma is a disorder in malignant plasma cell which mostly affects secondary organs such as bone, renal, bone marrow, immune as well as neurologic dysfunction. Multiple myeloma is a malignancy in clonal plasma cell that results from complex interactions between bone marrow stromal cells, malignant progenitor cells and the bone marrow microenvironment.
Refractory multiple myeloma can be defined as a disease that is progressive or non-responsive on therapy or within sixty days of last treatment in patients with less response. According to Janseen report 2016, an estimate of 38,000 new multiple myeloma cases were recorded each year in Europe. In addition to that, 28% multiple myeloma patients die within a year of diagnosis.
Refractory multiple myeloma treatment is expected to register significant growth in the market owing to increasing prevalence of multiple myeloma, advancement in research and development for innovative therapeutics for the refractory multiple myeloma treatment, introduction of monoclonal antibody for refractory multiple myeloma treatment are some of the factors driving the growth of the refractory multiple myeloma treatment market.
However, currently there is no standard of care for refractory multiple myeloma treatment. Moreover, cost associated with refractory multiple myeloma treatment and huge expenses in research and development in bringing out novel therapeutics may hinder the growth of the refractory multiple myeloma treatment market.
Treatment |
|
Distribution Channel |
|
Region |
|
To know more about delivery timeline for this report Contact Sales